KEYLYNK-007: Nivolumab plus Olaparib for Patients with HRR Mutated Solid Tumors
Condition: Solid Tumors
Sponsor: Merck Sharp & Dohme Corp.
Protocol MK-7339-007: A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer.
Eligible patients will have a tumor expressing one of the following alterations:
- BRCA1 mutation
- BRCA2 mutation
- Loss of heterozygosity score ≥16
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.